Literature DB >> 6711434

Comparison of hemodynamic responses to nifedipine and nitroprusside in severe chronic congestive heart failure.

U Elkayam, L Weber, B Torkan, C R McKay, S H Rahimtoola.   

Abstract

The hemodynamic effects of 20 to 40 mg of oral nifedipine were compared with those of intravenous nitroprusside in 11 patients with severe chronic congestive heart failure (CHF). In each patient, both drugs were administered to produce similar reduction of systemic vascular resistance (SVR) (29 +/- 13% with nifedipine and 29 +/- 12% with nitroprusside, difference not significant [NS]). At this comparable decrease in systemic vascular resistance, significant differences in hemodynamic responses to both drugs were noted: Nifedipine caused a smaller increase in cardiac index (20 +/- 20% vs 40 +/- 24%, p less than 0.02) and a larger decrease in mean blood pressure than nitroprusside (16 +/- 9% vs 8 +/- 10%, p less than 0.05). In addition, nifedipine produced a smaller decrease in mean pulmonary artery wedge pressure (13 +/- 24% vs 36 +/- 21%, p less than 0.001) and pulmonary vascular resistance than nitroprusside (6 +/- 42% vs 26 +/- 46%, NS). Mean right atrial pressure decreased with nitroprusside, from 10 +/- 7 to 5 +/- 3 mm Hg (p less than 0.05), but not with nifedipine (10 +/- 7 mm Hg before and after nifedipine administration, NS). Left ventricular stroke work index increased with nitroprusside (20 +/- 8 to 27 +/- 9 g-m/m2, p less than 0.05), but did not change with nifedipine (21 +/- 9 vs 21 +/- 10 g-m/m2, NS). These data show that nifedipine has an arteriolar dilatatory action in patients with CHF. However, compared with nitroprusside, nifedipine had a significantly larger hypotensive effect and had a lesser effect on right and left ventricular filling pressure, cardiac output and left ventricular function.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6711434     DOI: 10.1016/0002-9149(84)90087-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Radionuclide monitoring of left ventricular function after sublingual nifedipine administration at rest and during moderate physical activity.

Authors:  A Ferro; M Salvatore; A Cuocolo
Journal:  J Nucl Cardiol       Date:  2001 Nov-Dec       Impact factor: 5.952

2.  Effects of nifedipine on left ventricular diastolic dysfunction after myocardial infarction.

Authors:  R Scognamiglio; G Fasoli
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 3.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 4.  Calcium antagonists in patients with heart failure. A review.

Authors:  H Reicher-Reiss; E Barasch
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

5.  Comparison of haemodynamic effects of nifedipine and molsidomine in patients with coronary artery disease.

Authors:  M Kyriakidis; G Vyssoulis; P Sfikakis; C Kyriakidis; C Pitsavos; K Valsamis; V Nomikos; P Toutouzas
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 6.  The role of vasodilator therapy in the treatment of severe chronic heart failure.

Authors:  M Packer
Journal:  Drugs       Date:  1986       Impact factor: 9.546

7.  Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure.

Authors:  L Dei Cas; M Metra; R Ferrari; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.